146: Investing In The New Age Of Neuroscience

A combination of public and private investments in neuroscience, government grants, and charitable donations are helping accelerate a wave of advancements and opportunities in the field of neuroscience. Recent clinical trial success for the second significant, disease-modifying drug to treat Alzheimer’s is a critical milestone and a positive sign for the future of neuroscience. So, what does this mean for the healthcare investment landscape?

Jeff Spiegel, US Head of BlackRock Megatrend, International and Sector ETFs across index and active strategies talks about these latest breakthroughs in neuroscience and why it demands a closer look when considering healthcare opportunities in your portfolio.

Sources:

United States Census Bureau, “Older People Projected to Outnumber Children for First Time in U.S. History,” March 13, 2018; United Nations, “2022 Revision of World Population Prospects,” 2022; Eli Lilly, “Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease,” May 3, 2023; FactSet, Springer Adis Insight, 2022; BlackRock analysis; Alzheimer’s Association, ”2023 Alzheimer’s disease facts and figures,” April 19, 2023; Data Bridge Market Research, “Global Traumatic Brain Injuries Treatment Market – Industry Trends and Forecast to 2029,” February 2022; Kuehn, Bridget M. "WHO: Pandemic Sparked a Push for Global Mental Health Transformation." JAMA 328.1 (2022): 5-7; Biogen, “FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder,” August 4, 2023; PLOS One, “Adversarial confound regression and uncertainty measurements to classify heterogeneous clinical MRI in Mass General Brigham,” March 2, 2023; U.S. Food and Drug Administration, “New Drug Therapy Approvals 2022,” January 2023.

This content is for informational purposes only and is not an offer or a solicitation. Reliance upon information in this material is at the sole discretion of the listener.

In the UK and Non-European Economic Area countries, this authorised and regulated by the Financial Conduct Authority. In the European Economic Area, this is authorised and regulated by the Netherlands Authority for the Financial Markets.

For full disclosures go to Blackrock.com/corporate/compliance/bid-disclosures

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.